| Kathleen M Dungan, MD | |
|
543 Taylor Ave Fl 2, Columbus, OH 43203-1278 | |
| (614) 685-3333 | |
| (614) 366-0345 |
| Full Name | Kathleen M Dungan |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 23 Years |
| Location | 543 Taylor Ave Fl 2, Columbus, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598795098 | NPI | - | NPPES |
| 2664657 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 35087902 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ohio State University State Health System | Columbus, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Osu Internal Medicine Llc | 5496651408 | 984 |
News Archive
Tenet Healthcare Corporation today reported adjusted EBITDA of $218 million for the fourth quarter ended Dec. 31, 2009, an increase of $18 million, or 9.0 percent, as compared to $200 million for the fourth quarter of 2008.
To be sure, some progress has been made the past two years. Policymakers have enacted about $2.7 trillion in deficit reduction, primarily through cuts in discretionary spending and higher taxes on wealthy individuals. Yet what we have achieved so far is insufficient.
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
A new study indicates that individuals with diabetes may have an elevated risk of developing cancer before and immediately after a diabetes diagnosis. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings point to the need for a better understanding of the link between diabetes and cancer.
› Verified 2 days ago
| Entity Name | Osu Internal Medicine Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740231448 PECOS PAC ID: 5496651408 Enrollment ID: O20031210000658 |
News Archive
Tenet Healthcare Corporation today reported adjusted EBITDA of $218 million for the fourth quarter ended Dec. 31, 2009, an increase of $18 million, or 9.0 percent, as compared to $200 million for the fourth quarter of 2008.
To be sure, some progress has been made the past two years. Policymakers have enacted about $2.7 trillion in deficit reduction, primarily through cuts in discretionary spending and higher taxes on wealthy individuals. Yet what we have achieved so far is insufficient.
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
A new study indicates that individuals with diabetes may have an elevated risk of developing cancer before and immediately after a diabetes diagnosis. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings point to the need for a better understanding of the link between diabetes and cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kathleen M Dungan, MD 700 Ackerman Rd Ste 2120, Columbus, OH 43202-1559 Ph: (614) 685-3333 | Kathleen M Dungan, MD 543 Taylor Ave Fl 2, Columbus, OH 43203-1278 Ph: (614) 685-3333 |
News Archive
Tenet Healthcare Corporation today reported adjusted EBITDA of $218 million for the fourth quarter ended Dec. 31, 2009, an increase of $18 million, or 9.0 percent, as compared to $200 million for the fourth quarter of 2008.
To be sure, some progress has been made the past two years. Policymakers have enacted about $2.7 trillion in deficit reduction, primarily through cuts in discretionary spending and higher taxes on wealthy individuals. Yet what we have achieved so far is insufficient.
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
A new study indicates that individuals with diabetes may have an elevated risk of developing cancer before and immediately after a diabetes diagnosis. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings point to the need for a better understanding of the link between diabetes and cancer.
› Verified 2 days ago
Sethu M. Madhavan, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 W 10th Ave, Columbus, OH 43210 Phone: 614-293-3387 Fax: 614-366-0073 | |
Amrik Singh Khalsa, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 700 Childrens Dr, Columbus, OH 43205 Phone: 614-722-2000 Fax: 614-722-4966 | |
Samuel Y. Han, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-6255 Fax: 614-293-1456 | |
Dr. Ruchi Bhatia, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3400 Olentangy River Rd, Columbus, OH 43202 Phone: 614-754-5500 Fax: 614-457-9519 | |
Adam T. Ramey, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-7499 Fax: 614-366-2360 | |
Albert J. Cook, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 460 W 10th Ave, Columbus, OH 43210 Phone: 614-293-2957 Fax: 614-685-6533 | |
Walter G. Hanel Iv, MD, PHD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 460 W 10th Ave, Columbus, OH 43210 Phone: 614-293-3196 Fax: 614-293-4812 |